These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832 [TBL] [Abstract][Full Text] [Related]
6. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women. Schmidt MK; van den Broek AJ; Tollenaar RA; Smit VT; Westenend PJ; Brinkhuis M; Oosterhuis WJ; Wesseling J; Janssen-Heijnen ML; Jobsen JJ; Jager A; Voogd AC; van Leeuwen FE; van 't Veer LJ J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376189 [TBL] [Abstract][Full Text] [Related]
8. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients. Su L; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y Int J Cancer; 2020 Jun; 146(12):3335-3342. PubMed ID: 32037537 [TBL] [Abstract][Full Text] [Related]
9. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. Nyberg T; Frost D; Barrowdale D; Evans DG; Bancroft E; Adlard J; Ahmed M; Barwell J; Brady AF; Brewer C; Cook J; Davidson R; Donaldson A; Eason J; Gregory H; Henderson A; Izatt L; Kennedy MJ; Miller C; Morrison PJ; Murray A; Ong KR; Porteous M; Pottinger C; Rogers MT; Side L; Snape K; Walker L; Tischkowitz M; Eeles R; Easton DF; Antoniou AC Eur Urol; 2020 Jan; 77(1):24-35. PubMed ID: 31495749 [TBL] [Abstract][Full Text] [Related]
10. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Kwan E; Jack E; Vesprini DJ; Kuperstein G; Abrahamson JL; Fan I; Wong B; Narod SA Am J Hum Genet; 2001 Mar; 68(3):700-10. PubMed ID: 11179017 [TBL] [Abstract][Full Text] [Related]
11. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. Domchek SM; Friebel TM; Singer CF; Evans DG; Lynch HT; Isaacs C; Garber JE; Neuhausen SL; Matloff E; Eeles R; Pichert G; Van t'veer L; Tung N; Weitzel JN; Couch FJ; Rubinstein WS; Ganz PA; Daly MB; Olopade OI; Tomlinson G; Schildkraut J; Blum JL; Rebbeck TR JAMA; 2010 Sep; 304(9):967-75. PubMed ID: 20810374 [TBL] [Abstract][Full Text] [Related]
12. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Gabai-Kapara E; Lahad A; Kaufman B; Friedman E; Segev S; Renbaum P; Beeri R; Gal M; Grinshpun-Cohen J; Djemal K; Mandell JB; Lee MK; Beller U; Catane R; King MC; Levy-Lahad E Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14205-10. PubMed ID: 25192939 [TBL] [Abstract][Full Text] [Related]
13. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502 [TBL] [Abstract][Full Text] [Related]
14. Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry. Menes TS; Terry MB; Goldgar D; Andrulis IL; Knight JA; John EM; Liao Y; Southey M; Miron A; Chung W; Buys SS Breast Cancer Res Treat; 2015 Jun; 151(3):653-60. PubMed ID: 25975955 [TBL] [Abstract][Full Text] [Related]
15. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. Evans DG; Shenton A; Woodward E; Lalloo F; Howell A; Maher ER BMC Cancer; 2008 May; 8():155. PubMed ID: 18513387 [TBL] [Abstract][Full Text] [Related]
16. Analysis of cancer risk and BRCA1 and BRCA2 mutation prevalence in the kConFab familial breast cancer resource. Mann GJ; Thorne H; Balleine RL; Butow PN; Clarke CL; Edkins E; Evans GM; Fereday S; Haan E; Gattas M; Giles GG; Goldblatt J; Hopper JL; Kirk J; Leary JA; Lindeman G; Niedermayr E; Phillips KA; Picken S; Pupo GM; Saunders C; Scott CL; Spurdle AB; Suthers G; Tucker K; Chenevix-Trench G; Breast Cancer Res; 2006; 8(1):R12. PubMed ID: 16507150 [TBL] [Abstract][Full Text] [Related]
17. Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations. Lee JS; John EM; McGuire V; Felberg A; Ostrow KL; DiCioccio RA; Li FP; Miron A; West DW; Whittemore AS Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):359-63. PubMed ID: 16492929 [TBL] [Abstract][Full Text] [Related]
18. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Metcalfe K; Lynch HT; Ghadirian P; Tung N; Olivotto I; Warner E; Olopade OI; Eisen A; Weber B; McLennan J; Sun P; Foulkes WD; Narod SA J Clin Oncol; 2004 Jun; 22(12):2328-35. PubMed ID: 15197194 [TBL] [Abstract][Full Text] [Related]
19. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414 [TBL] [Abstract][Full Text] [Related]
20. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]